Wuhan Kefu New Drug

Wuhan Kefu New Drug (also known as Conform Pharm) is an innovative biopharmaceutical company focused on pediatrics, dermatology, and ophthalmology. The company leverages its proprietary nanotechnology-based delivery platforms, including nanoemulsion, lipid carriers, and nanocrystals, to develop improved and innovative drugs. Its lead product, He Meijia® (Propranolol Hydrochloride Oral Solution), is the first domestic treatment of its kind approved for infantile hemangioma in China. The pipeline includes TML-023, a topical treatment for hemangioma in Phase 2, and LS21031, a PDE4 inhibitor for depression in early clinical development.